Skip to content

Master your MANTA: MANTA™ Training Academy

Get trained on the first biomechanical device for large bore femoral arterial access site closure

This program is designed to educate on proper MANTA Device deployment technique to help you provide your patients with positive outcomes and minimise complications. 

Over nine months, this program will equip you with the necessary support and guidance to feel confident in closing large bore femoral access sites with the MANTA Vascular Closure Device.

Request for Demo

Innovation can save lives.

AND helps shorten time to discharge.

We know that the potential impact of bleeding complications can result in a higher cost of care per patient, potentially resulting in a 2x increase in hospital length of stay, a 3x increase in mortality, and a 60% increase in healthcare costs.7 When you choose the MANTA Device, its innovative design achieves low major complication rates and rapid time to hemostasis, helping your patients get home faster.8,2b,d
Manta devices

Delivering the efficiency you were looking for

MANTA™ provides a more efficient experience by shortening recovery time and reducing procedural costs of large-bore closures.

MANTAᵀᴹ is the first biomechanical device for large bore femoral arterial access site closure, driving improved procedural efficiencies.1,8

Hear from Other Physicians

MANTA™ Training Academy: Curriculum

In-service Training and Demonstration

 

Platform

In-person, facilitated by Teleflex Trainer

 

Goal

Introduce the MANTA Vascular Closure Device and  deployment procedure

 

Duration

Half-day

 

• Product overview
• Access recommendations
• Deployment video and process
• Step-by-step deployment guide
• Hands-on with dry models

 

• In-service completion form

Live Case Training

 

Platform

In-person, facilitated by Teleflex Trainer

 

Goal

Gain procedural accuracy and proper deployment technique with the MANTA Device

 

Pathway to credentialing

Case support with Teleflex trainer which enables MANTA certification

Review Training and

Case Observations

 

Platform

In-person facilitated by Teleflex Trainer

 

Goal

Ensure continued technique accuracy through follow-up training and case observation

 

Goal

1-2 days at 3, 6, and 9 months Practical Training

 

Requirement for 

Phase 1 Completion


A physician signed in-service completion  form is required to advance to Phase 2–Live Case Training

Requirement for 

Phase 2 Completion


Successfully deploy 5 guided and 5 supervised cases to advance to Phase 3-Continuous Learning

Requirement for 

Phase 3 Completion


Deployment review at each milestone

Contact Us

Connect with our Customer Specialists.

Find out more about the MANTA™ Training Academy.

Scan the QR code below.

Chat with our Customer Specialist.

Frequently Asked Questions

This program is designed to educate on proper MANTA Device deployment technique to help you provide your patients with positive outcomes and minimise complications. Over the next nine months, this program will equip you with the necessary support and guidance to feel confident in closing large bore femoral access sites with the MANTA Vascular Closure Device.

The initial product introduction is critical to ensure all designated staff fully understand the unique features and benefits of the MANTA Device. This training timeframe supports a greater understanding of the purpose-designed MANTA Device, leading to greater technical accuracy when using the device and achievement of successful large bore femoral arterial access site closure.

Based on extensive physician training in Europe over the last several years, this cadence of five guided cases, followed by a minimum of five supervised cases, supports technique accuracy. Teleflex trainers will provide guidance through the initial 10 cases* to support proper use of the device, educate on proper deployment technique and inspire physician confidence with the MANTA Device.

For continued success closing large bore femoral arterial access sites with the MANTA Device, it is extremely important that deployment nuances are mastered and each step is precisely executed. The three, six and nine-month milestones provide opportunity to experience a range of clinical scenarios and gain experience troubleshooting in more challenging cases. This cadence of observations promotes adherence to proper technique nuances, opportunity to provide clinical reminders and corrections as needed.

REFERENCES:
  1. Data on file at Teleflex.
  2. The SAFE MANTA IDE Clinical Trial.
    1. A single MANTA® Vascular Closure Device was deployed in 99.6% of subjects in IDE trial.
    2. The MANTA® Device demonstrated a time to hemostasis (TTH) of 24 seconds median time (65 seconds mean time) from deployment to hemostasis, which is lower than published rates for Perclose ProGlide® where Perclose ProGlide® demonstrated a TTH of 9.8 ± 17 minutes (588 ± 1,020 seconds).3
    3. 97.7% Technical Success, defined as percutaneous vascular closure obtained with the MANTA® Device without the use of unplanned endovascular or surgical intervention.
    4. Major Complications defined as composite of: i) vascular injury requiring surgical repair/stent-graft; ii) bleeding requiring transfusion; iii) lower extremity ischemia requiring surgical repair/additional percutaneous intervention; iv) nerve injury (permanent or requiring surgical repair); and v) infection requiring IV antibiotics and/or extended hospitalization.
    5. Time to Hemostasis defined as: The elapsed time between MANTA® deployment (withdrawal of sheath from artery) and first observed and confirmed arterial hemostasis (no or minimal subcutaneous oozing and the absence of expanding or developing hematoma).
    6. Technical success defined as: Percutaneous vascular closure obtained with the MANTA® Device without the use of unplanned endovascular or surgical intervention.
      Study sponsored by Teleflex Incorporated or its affiliates.
  3. Nelson PR, et al. A multicenter, randomized, controlled trial of totally percutaneous access versus open femoral exposure for endovascular aortic aneurysm repair (the PEVAR trial). J Vasc Surg. 2014 May;59(5):1081-1193.
  4. Krajcer, Zvonimir, et al. “Pivotal Clinical Study to Evaluate the Safety and Effectiveness of the MANTA Vascular Closure Device During Percutaneous EVAR and TEVAR Procedures.” Journal of Endovascular Therapy, 20 Mar. 2020, p. 152660282091222., doi:10.1177/1526602820912224.
  5. Généreux P, et al. Vascular complications after transcatheter aortic valve replacement. J Am Coll Cardiol. 2012 Sept 18;60(12):1043-1052.
  6. Lauten A, et al. Percutaneous left-ventricular support with the Impella 2.5®-assist device in acute cardiogenic shock: results of the Impella-EUROSHOCK-registry. Circ Heart Fail. 2013 Jan;6(1):23-30.
  7. Redfors et al, Mortality, Length of Stay and Cost Implications of Procedural Bleeding After Percutaneous Intervention Using Large-Bore Catheters, Journal of the American Medical Association (JAMA) Cardiology, Published online March 18, 2017. *Adjusted relative risk
  8. Megaly M, et al. Outcomes with MANTA Device For Large-Bore Access Closure After Transcatheter Aortic Valve Replacement: A Meta-Analysis. Structural Heart, 13 Aug. 2020, DOI: 10.1080/24748706.2020.1809755.
Safety Information
INDICATIONS FOR USE:The MANTA Vascular Closure Device is indicated for closure of femoral arterial access sites while reducing time to hemostasis following the use of 10-20F devices or sheaths (12-25F OD) in endovascular catheterization procedures. CONTRAINDICATIONS: The MANTA Device is contraindicated in the following • Severe calcification of the access vessel. • Severe peripheral artery disease. • Puncture in the origin of the profundal femoral artery, above the inguinal ligament, or above the most inferior border of the epigastric artery (IEA). • Sheath insertion in vessel other than the femoral artery. • Marked tortuosity of the femoral or iliac artery. • Marked obesity or cachexia (BMI >40 or <20). • Blood pressure >180 mmHg. • Patients who cannot be anti-coagulated for the procedure. WARNINGS: 1) Do not use if the puncture site is proximal to the inguinal ligament or above the most inferior border of the epigastric artery (IEA), as this may result in retroperitoneal bleeding. 2) Do not use in patients with severe calcification of the access vessel and/or common femoral artery stenosis resulting in a vessel <5mm in diameter for the 14F MANTA or <6mm in diameter for the 18F MANTA, or >50% diameter femoral or iliac artery stenosis. 3) Do not use in patients with severe peripheral vascular disease, as evidenced by severe claudication when ambulating <100 feet, weak or absent pulses in the affected limb, or ABI <0.5 at rest. 4) Do not use if the temperature indicator dot on package has changed from light gray to dark gray or black. 5) Do not use if the package is damaged or any portion of the package has been previously opened. 6) Do not use if the items in the package appear damaged or defective in any way. 7) Do not REUSE or RESTERILIZE. The MANTA Device is single use only. The MANTA Device contains bioresorbable materials that cannot be reused or re-sterilized. Reuse or re-sterilization may cause degradation to the integrity of the device, leading to device failure which may result in patient injury, illness, or death. 8) Do not use the MANTA Device where bacterial contamination of the procedure sheath or surrounding tissues may have occurred, as this may result in infection. 9) Do not use if the MANTA delivery system becomes kinked. 11) Do not inflate a contralateral balloon in the femoral or iliac artery during MANTA Sheath exchange or the MANTA Closure procedure. 12) Do not use MANTA if there has been a femoral artery puncture in same vessel within the prior 30 days, recent femoral artery puncture in same groin that has not healed appropriately, and/or recent (<30 days) vascular closure device placement in same femoral artery. 13) Do not use if the puncture site is at or distal to the bifurcation of the superficial femoral and profunda femoris artery, as this may result in the (a) anchor catching on the bifurcation or being positioned incorrectly, and/or (b) collagen deposition into the vessel. 14) Do not use if there is difficult dilation from initial femoral artery access (e.g., damaging or kinking dilators) while step dilating up to the large-bore device. Difficult dilation of the puncture tract due to scar tissue may lead to swelling of surrounding tissue, thus compromising the accuracy of the puncture depth determined during the puncture location procedure. 15) Do not use if sheath insertion is in a vessel other than the femoral artery. 16) Do not use if there is marked tortuosity of the femoral or iliac artery. 17) Do not use if the patient has marked obesity or cachexia (BMI>40 kg/m2 or <20 kg/m2). 18) Do not use if the patient has post-procedure blood pressure>180 mmHg that cannot be lowered prior to access site closure. 19) Do not use in patients who cannot be adequately anticoagulated for the procedure. 20) Do not use the MANTA Device in patients with known allergies to bovine products, collagen and/or collagen products, polyglycolic or polylactic acid polymers, stainless steel or nickel. PRECAUTIONS: 1) The MANTA Device should only be used by a licensed physician or healthcare provider trained in the use of this device. 2) This device contains a small radiopaque stainless-steel lock that is implanted in the puncture tract. See MRI information in these instructions for use and patient implant card. 3) In the event that bleeding from the femoral access site persists after the use of the MANTA Device, the physician should assess the situation. Based on the physician assessment of the amount of bleeding, use manual or mechanical compression, application of balloon pressure from a secondary access site, placement of a covered stent, and/or surgical repair to obtain hemostasis. POTENTIAL ADVERSE EVENTS: The following potential adverse events related to the deployment of Vascular Closure Devices have been identified: 1) Ischemia of the leg or stenosis of the femoral artery. 2) Local trauma to the femoral or iliac artery wall, such as dissection. 3) Retroperitoneal bleeding as a result of access above the inguinal ligament or the most inferior border of the epigastric artery (IEA). 4) Perforation of iliofemoral arteries, causing bleeding/hemorrhage. 5) Thrombosis formation or embolism. 6) Nerve damage or neuropathy. 7) Other access site complications leading to bleeding, hematoma, pseudoaneurysm, or arterio-venous fistula, possibly requiring blood transfusion, surgical repair, and/or endovascular intervention. Potential Adverse Events associated with any large bore intervention, including the use of the MANTA Vascular Closure Device, include but are not limited to: Arterial damage; Arterio-venous fistula; Bradycardia; Compartment syndrome; Death related to the procedure; Deep vein thrombosis; Ecchymosis; Edema; Infection at the puncture site which may require antibiotics or extended hospitalization; Inflammatory response; Late arterial bleeding; Oozing from the puncture site; Pressure in groin/access site region; Vessel laceration or trauma; Wound dehiscence. Please see the instructions for use for complete product information. Not all products are available in all regions. Please contact customer service to confirm availability in your region. Teleflex is a global provider of medical technologies designed to improve the health and quality of people’s lives. We apply purpose driven innovation – a relentless pursuit of identifying unmet clinical needs – to benefit patients and healthcare providers. Our portfolio is diverse, with solutions in the fields of vascular and interventional access, surgical, anesthesia, cardiac care, urology, emergency medicine and respiratory care. Teleflex employees worldwide are united in the understanding that what we do every day makes a difference. Corporate Office Phone +1 610 225 6800, 550 E. Swedesford Road, Suite 400, Wayne, PA 19087, USA Regional Offices International: Phone +353 (0)9 06 46 08 00, orders.intl@teleflex.com, Teleflex Medical Europe Ltd.,  IDA Business and Technology Park, Dublin Road, Athlone, Co Westmeath, Ireland Australia: Phone 1300-360-226 (Domestic calls only), austCS@teleflex.com, Level 4, 197 Coward St Mascot NSW 2020 New Zealand: Phone 0800 601 100 (Domestic calls only), nzcs@teleflex.com, 21 Airpark Drive, Mangere, Auckland 2022 For more information, please visit https://teleflex.com/anz Teleflex, the Teleflex logo, and MANTA are trademarks or registered trademarks of Teleflex Incorporated or its affiliates, in the U.S. and/or other countries. All other trademarks or registered trademarks are property of their respective owners. MCI-101048.